om a discounted cash flow analysis that uses a WACC of 10% and a 2% terminal growth rate. The main drivers are Tecfidera. the hemophilia franchise. Plegridy/Avonex and the pipeline Bull DCF Case $502 Outsized penetration of Tecfidera into both the US and ROW markets; a faster Hemophilia launch and more con